KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Long-Term Debt Repayments (2018 - 2025)

BeOne Medicines (ONC) has disclosed Long-Term Debt Repayments for 5 consecutive years, with $14.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Long-Term Debt Repayments rose 39.89% to $14.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $35.7 million, a 27.29% increase, with the full-year FY2025 number at $35.7 million, up 27.29% from a year prior.
  • Long-Term Debt Repayments was $14.6 million for Q4 2025 at BeOne Medicines, up from $4.3 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $14.6 million in Q4 2025 to a low of -$1.5 million in Q2 2023.
  • A 3-year average of $6.5 million and a median of $4.7 million in 2023 define the central range for Long-Term Debt Repayments.
  • Biggest YoY gain for Long-Term Debt Repayments was 816.61% in 2024; the steepest drop was 57.92% in 2024.
  • BeOne Medicines' Long-Term Debt Repayments stood at $5.2 million in 2023, then skyrocketed by 99.89% to $10.4 million in 2024, then skyrocketed by 39.89% to $14.6 million in 2025.
  • Per Business Quant, the three most recent readings for ONC's Long-Term Debt Repayments are $14.6 million (Q4 2025), $4.3 million (Q3 2025), and $12.6 million (Q2 2025).